Abstract:Inspired by the multivalent effect of surface‐displayed ligands on target association, an assembly‐glued strategy allows for development of supramolecular covalent inhibitors with the display‐induced proximity between noncovalent ligands and warheads. This concept is exemplified with a hypoxia‐activated supramolecular covalent inhibitor undergoing covalent conjugation with target protein EGFR for cancer therapy. Targeted covalent inhibitors are promising for drug discovery and challenged by the strict structural features for target proteins to sustain proximity‐induced conjugations. Herein, an assembly‐glued strategy is reported to create surface‐displayed supramolecular covalent inhibitors that leverage the display‐induced proximity between noncovalent ligands and warheads. The ligand and warhead are obtained via attaching an epidermal growth factor receptor (EGFR)‐binding segment or nitroreductase (NTR)‐activated moiety to bola‐amphiphilic peptides, respectively. Co‐assembling the ligand and warhead with a filler peptide glues them and forms the surface‐displayed covalent inhibitor. While the ligand associates with EGFR, the warhead undergoes NTR‐induced cysteine conjugation facilitated by the ligand‐EGFR association. In vitro studies show the reliable hypoxia‐activated inhibition of EGFR phosphorylation and enhanced cytotoxicity of the covalent inhibitor under hypoxic condition. In addition, this strategy also allows for creating covalent inhibitors targeting proteins without small molecular covalent drugs, due to the display‐induced proximity between ligands and warheads. In vivo results illustrate the prolonged retention of the covalent inhibitor and its efficacy in inhibiting tumor growth. These findings demonstrate that simultaneous surface display of ligands and warheads via assembly adhesives allows for implementation of covalent inhibition functions, thus providing a new strategy for developing covalent inhibitors in the future.

Structural Insights into Notum Covalent Inhibition

Small-molecule inhibitors of carboxylesterase Notum

Designed switch from covalent to non-covalent inhibitors of carboxylesterase Notum activity

Design of a Potent, Selective, and Brain-Penetrant Inhibitor of Wnt-Deactivating Enzyme Notum by Optimization of a Crystallographic Fragment Hit

Carboxylesterase Notum Is a Druggable Target to Modulate Wnt Signaling

Structural Analysis and Development of Notum Fragment Screening Hits

Virtual Screening Directly Identifies New Fragment-Sized Inhibitors of Carboxylesterase Notum with Nanomolar Activity

Identification and Structure-Function Analyses of an Allosteric Inhibitor of the Tyrosine Phosphatase PTPN22.

Notum deacylates octanoylated ghrelin

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Synthesis and Preliminary Evaluation of Peptidomimetic Inhibitors of Human Beta-Secretase

Unveiling the Novel Characteristics of IGPD Polymer and Inhibitors Binding Affinities Using 12-6-4 LJ-type Nonbonded Mn2+ Model

Chalcone derivatives as novel, potent and selective inhibitors against human Notum: Structure–activity relationships and biological evaluations

Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.

Computational and Experimental Studies of Inhibitor Design for Aldolase A

Assembly‐Glued Ligands and Warheads for Hypoxia‐Activatable Supramolecular Covalent Inhibitors

NOTUM Plays a Bidirectionally Modulatory Role in the Odontoblastic Differentiation of Human Stem Cells from the Apical Papilla Through the WNT/β-catenin Signaling Pathway

Structural insights into the orthosteric inhibition of P2X receptors by non-ATP analog antagonists

Structural and Biochemical Analyses of the Catalysis and Potency Impact of Inhibitor Phosphoribosylation by Human Nicotinamide Phosphoribosyltransferase

Structural insights into the orthosteric inhibition of P2X receptors by non-ATP-analog antagonists